LabCorp Announces Definitive Agreement to Acquire Orchid Cellmark Inc.

Acquisition Price of $2.80 per Share in All Cash Transaction BURLINGTON, N.C. & PRINCETON, N.J., Apr 06, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) and Orchid Cellmark Inc. (NASDAQ: ORCH), an international provider of DNA testing services

Conversion Right Triggered for LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C., Apr 04, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C., Mar 14, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that for the period of March 12, 2011 to September 11, 2011, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms

LabCorp is Scheduled to Present at the Barclays Capital 2011 Global Healthcare Conference

BURLINGTON, N.C., Mar 09, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the Barclays Capital 2011 Global Healthcare Conference in Miami Beach, FL.

LabCorp is Scheduled to Speak at RBC Capital Markets' 2011 Healthcare Conference

BURLINGTON, N.C., Feb 23, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the RBC Capital Markets' 2011 Healthcare Conference in New York City, NY.

Laboratory Corporation of America(R) Holdings Announces 2010 Fourth Quarter and Full Year Results

Revenue Growth Drives Q4 Adjusted EPS of $1.34, up 15.5%, and Operating Cash Flow of $259.2 Million Board Authorizes New $500 Million Share Repurchase Program BURLINGTON, N.C., Feb 10, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today announced

LabCorp publishes the Virology Report on its newly launched "Research" web page http://www.labcorp.com/research/virology

BURLINGTON, N.C., Jan 31, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today released the Virology Report on its "Research" web page, an unprecedented resource for scientists and healthcare professionals.

LabCorp is Scheduled to Present at the 29th Annual J.P. Morgan Healthcare Conference

BURLINGTON, N.C., Jan 05, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the 29 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C., Jan 03, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and

N. Anthony Coles, M.D. Named to LabCorp(R) Board of Directors

BURLINGTON, N.C., Dec 07, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE:LH) today announced that N. Anthony Coles, M.D., has been elected to its Board of Directors, effective January 1, 2011. Dr. Coles is President and CEO of Onyx Pharmaceuticals, Inc.